Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CCKBR | P32239 | 1/20 | 0.46 |
| ▸ | CCR1 | P32246 | 4/20 | 0.45 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.40 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ITGA1 | P56199 | 1/20 | 0.39 |
| ▸ | MC4R | P32245 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13994327 | 0.91 | TRPV4 (0.52) | TRPV4CCR1MEN1KMT2AITGA1 | |
| SCHEMBL5004460 | 0.89 | TRPV4 (0.53) | TRPV4CCR1MEN1KMT2AMC4R | |
| SCHEMBL4976334 | 0.87 | TRPV4 (0.68) | TRPV4MAPK1CCKBRCCR1ITGB1 | |
| SCHEMBL4978992 | 0.85 | CCKBR (0.50) | CCKBRITGB1ITGA4MEN1KMT2A | |
| SCHEMBL13994326 | 0.83 | TRPV4 (0.50) | TRPV4MAPK1CCR1MEN1KMT2A | |
| SCHEMBL4980366 | 0.81 | TRPV4 (0.80) | TRPV4CCR1 | |
| SCHEMBL4971936 | 0.80 | TRPV4 (0.47) | TRPV4MEN1KMT2AMC4R | |
| SCHEMBL5007943 | 0.75 | TRPV4 (0.70) | TRPV4CCR1MEN1KMT2AMC4R | |
| SCHEMBL4132204 | 0.75 | MAPK1 (0.45) | TRPV4MAPK1CCR1MEN1KMT2A | |
| SCHEMBL4132203 | 0.75 | MAPK1 (0.45) | TRPV4MAPK1CCR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318945-A1 | Novel Compounds | CASILLAS LINDA N | 2008-12-25 | — | — | US | claimed |
| US-20080318945-A1 | Novel Compounds | CASILLAS LINDA N | 2008-12-25 | — | — | US | disclosed |
| US-20080318945-A1 | Novel Compounds | CASILLAS LINDA N | 2008-12-25 | — | — | US | disclosed |
| US-20080318945-A1 | Novel Compounds | CASILLAS LINDA N | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318945-A1 | Novel Compounds | TRPV4, TRPV1, TRPV3 | TRPV4 1/4885MAPK1 1612/4885CCKBR 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.